Greenwich LifeSciences (GLSI) Other Non-Current Liabilities (2024 - 2026)
Greenwich LifeSciences' (GLSI) quarterly Other Non-Current Liabilities came in at $673819.0 in Q4 2025, up 120.0% YoY from $306281.0 in Q4 2024, and up 120.0% on a QoQ basis from $306281.0 in Q2 2025.
Powered by 
Analysis
Greenwich LifeSciences (GLSI) Other Non-Current Liabilities (2024 - 2026) Analysis & Trends
Greenwich LifeSciences (GLSI) has 2 years of Other Non-Current Liabilities data on file, last reported at $673819.0 in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 120.0% year-over-year to $673819.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $673819.0 (up 120.0% YoY) and the FY2025 annual result came in at $673819.0, up 120.0% from the prior year.
- Other Non-Current Liabilities rose to $673819.0 in Q4 2025, from $306281.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $673819.0 in Q4 2025 to a low of $306281.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Greenwich LifeSciences | 231.59 Mn | 231.59 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 673,819.00 |
| Dec 31, 2025 | 673,819.00 |
| Jun 30, 2025 | 306,281.00 |
| Mar 31, 2025 | 306,281.00 |
| Dec 31, 2024 | 306,281.00 |